Market News & Trends
Endogena Therapeutics Receives Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa
Endogena Therapeutics Inc. recently announced the US FDA has designated the investigation of EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Track…
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
Immutep Limited recently announced the investigator-initiated INSIGHT-003 trial has reached its enrolment target of 20 patients with 1L NSCLC. INSIGHT-003 is the first trial evaluating…
BD Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery
BD (Becton, Dickinson and Company) recently announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample…
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis
First Wave BioPharma, Inc. recently announced the first patient was screened for the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation…
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia & Weight Loss
Artelo Biosciences, Inc. recently announced enrollment in the final cohort of the Phase 1b stage of its Cancer Appetite Recovery Study (CAReS) is now complete.…
Frontera Therapeutics Doses First Patient in a Clinical Trial of Gene Therapy for the Treatment of Wet AMD
Frontera Therapeutics recently announced it has dosed the first patient in a clinical trial of its innovative gene therapy product, FT-003, at the Ophthalmology Hospital…
Seqens Group Opens Flagship Pharmaceutical R&D Center in Greater Boston
Seqens Group recently announced it has opened Seqens Boston R&D Center, a state-of-the-art, 15,000-sq-ft R&D center in Devens, MA. Serving as one of the company’s…
Gerresheimer Presents its New Clinical Trial Kit to Accelerate Drug Development
Gerresheimer presents its new Clinical Trial Kit at Pharmapack in Paris. This kit consists of sterile Gx RTF vials in nest and tub or tray…
Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset
Akoya Biosciences, Inc. recently announced it will present results from a novel same-section, spatial multiomic study at the Advances in Genome Biology and Technology (AGBT)…
Aptamer Group Partners With BaseCure Therapeutics to Develop New Targeted Gene Therapies
Aptamer Group plc recently announced a new partnership with BaseCure Therapeutics for the development of Optimer-targeted gene therapies. The ability to precisely target gene therapies,…
EXCLUSIVE ONLINE CONTENT

Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….

Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….

Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….